ArticleBMC cancer2019

Combined targeting of HER-2 and HER-3 represents a promising therapeutic strategy in colorectal cancer.

Lena-Christin Conradi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.